Related Experiment Video
Updated: Jan 21, 2026
06:48
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
Published on: May 31, 2020
6.3K
Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know?
Charissa A C Jessurun1, Alexander F C Hulsbergen2,3,4, Logan D Cho2,5
1Faculty of Medicine, University of Amsterdam/Amsterdam University Medical Center, Location Academic Medical Center (AMC), Meibergdreef 9, 1105 AZ, Amsterdam, Noord-Holland, The Netherlands.
Journal of Neuro-Oncology
|July 27, 2019
Summary
Dexamethasone (DXM) dosing for brain tumors lacks clear evidence. Lower doses may be as effective as higher doses with fewer side effects, but more research is needed.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
- Evidence-based medicine
Background:
- Dexamethasone (DXM) is commonly used for managing edema in malignant brain tumors.
- Optimal dosing strategies for DXM in this patient population remain unclear.
Purpose of the Study:
- To systematically review literature on dexamethasone (DXM) dosage and scheduling in malignant brain tumor patients.
- To evaluate the relationship between DXM dose and clinical outcomes, including edema, symptoms, adverse events, and survival.
Main Methods:
- Systematic literature search across multiple databases (PubMed, Embase, Web of Science, etc.).
- Inclusion of studies reporting on edema volume, symptomatic relief, adverse events, and survival in glioma or brain metastasis (BM) patients treated with DXM.
- Qualitative review of fifteen selected articles due to study heterogeneity precluding meta-analysis.
Main Results:
- Most studies utilized a 16 mg/day dose of DXM, often divided as 4 mg four times daily.
- For brain metastases (BM), higher DXM doses may increase adverse events without improving clinical condition and potentially shorten survival in palliative settings.
- For glioma, DXM may improve symptoms, but evidence on optimal dosing for edema reduction and survival is conflicting.
Conclusions:
- Current evidence on dexamethasone (DXM) safety and efficacy in malignant brain tumors is limited and contradictory.
- Lower DXM doses may be non-inferior to higher doses in specific scenarios.
- Further comparative research is essential, particularly considering the rise of immunotherapy for brain tumors.
More Related Videos
Related Concept Videos
02:55The Evidence for Evolution
47.7K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
47.7K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
215
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
215
01:21Dose Size and Dosing Frequency: Determination Methods
281
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
281
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
229
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
229
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
5.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.4K
01:03Dose-Response Relationship: Overview
5.0K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.0K